Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Symlin Reviewer Cautions Against Diabetes Claims For Anorexic Agents

Executive Summary

FDA should be wary of approving a diabetes claim for a drug whose mechanism of action is reducing body weight, FDA reviewer Robert Misbin, MD, said in briefing materials prepared for the advisory committee review of Amylin's Symlin.

You may also be interested in...



Amylin Symlin Study Will Evaluate Hypoglycemia Risk During Dose Initiation

Amylin is planning a six-week Symlin safety study to evaluate the increased incidence of hypoglycemia associated with the antidiabetic agent, the company said following a July 26 FDA advisory committee recommendation against approval of the drug.

Roche Agenda For 2001 Includes Kytril NDA For Post-Op Use, Pegasys Launch

Roche plans to file an NDA during 2001 for use of the anti-emetic Kytril in post-operative nausea and vomiting, the company said during a recent analysts meeting in Basel.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
UsernamePublicRestriction

Register

PS038292

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel